Gram-Negative Infections | Unmet Need | ESBL | US/EU | 2016
The increasing prevalence and severity of Gram-negative infections (GNIs) caused by extended-spectrum beta-lactamase (ESBL)-producing pathogens have emerged as a global public health concern. Recent surveillance studies find that an increasing proportion of ESBL-producing pathogens are also associated with resistance to other classes of antibiotics, further limiting therapeutic options. As such, new antibiotics with activity against ESBL-producing Gram-negative pathogens represent a key unmet need in the GNI therapy market.
Related Market Assessment Reports
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…
Report
Chronic Urticaria – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Spontaneous Urticaria (US)
The treatment landscape for chronic spontaneous urticaria (CSU) remains largely driven by oral therapies, including approved antihistamines and off-label agents such as DMARDs and…
